Time-differentiated target temperature management after out-of-hospital cardiac arrest : a multicentre, randomised, parallel-group, assessor-blinded clinical trial (the TTH48 trial): study protocol for a randomised controlled trial by Kirkegaard, Hans et al.
STUDY PROTOCOL Open Access
Time-differentiated target temperature
management after out-of-hospital cardiac
arrest: a multicentre, randomised, parallel-
group, assessor-blinded clinical trial
(the TTH48 trial): study protocol for a
randomised controlled trial
Hans Kirkegaard1*, Bodil S Rasmussen2, Inge de Haas2, Jørgen Feldbæk Nielsen3, Susanne Ilkjær4, Anne Kaltoft5,
Anni Nørregaard Jeppesen1, Anders Grejs1, Christophe Henri Valdemar Duez1, Alf Inge Larsen6,7, Ville Pettilä8,9,
Valdo Toome10, Urmet Arus11, Fabio Silvio Taccone12, Christian Storm13, Markus B. Skrifvars8 and Eldar Søreide14,15
Abstract
Background: The application of therapeutic hypothermia (TH) for 12 to 24 hours following out-of-hospital cardiac
arrest (OHCA) has been associated with decreased mortality and improved neurological function. However, the
optimal duration of cooling is not known. We aimed to investigate whether targeted temperature management
(TTM) at 33 ± 1 °C for 48 hours compared to 24 hours results in a better long-term neurological outcome.
Methods: The TTH48 trial is an investigator-initiated pragmatic international trial in which patients resuscitated
from OHCA are randomised to TTM at 33 ± 1 °C for either 24 or 48 hours. Inclusion criteria are: age older than 17
and below 80 years; presumed cardiac origin of arrest; and Glasgow Coma Score (GCS) <8, on admission. The
primary outcome is neurological outcome at 6 months using the Cerebral Performance Category score (CPC) by
an assessor blinded to treatment allocation and dichotomised to good (CPC 1–2) or poor (CPC 3–5) outcome.
Secondary outcomes are: 6-month mortality, incidence of infection, bleeding and organ failure and CPC
at hospital discharge, at day 28 and at day 90 following OHCA. Assuming that 50 % of the patients treated for
24 hours will have a poor outcome at 6 months, a study including 350 patients (175/arm) will have 80 % power
(with a significance level of 5 %) to detect an absolute 15 % difference in primary outcome between treatment
groups. A safety interim analysis was performed after the inclusion of 175 patients.
Discussion: This is the first randomised trial to investigate the effect of the duration of TTM at 33 ± 1 °C in adult OHCA
patients. We anticipate that the results of this trial will add significant knowledge regarding the management of cooling
procedures in OHCA patients.
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Background
Out-of-hospital cardiac arrest (OHCA) is a major health
problem associated with significant morbidity and mortal-
ity. Post-anoxic brain damage remains the leading cause
of death in those patients surviving admission to the in-
tensive care unit (ICU) [1]. Extended brain injury is caused
by a period of ischaemia followed by the reperfusion phase
(the so-called ‘ischaemia-reperfusion injury’) [2], which will
result in the activation of several pathophysiological path-
ways, including the release of glutamate, intracellular cal-
cium accumulation, production of reactive oxygen species
and an increased inflammatory response. These phenom-
ena will induce neuronal and astroglial cell death with irre-
versible loss of cerebral functions [3–5].
Previous animal studies have shown beneficial effects
on survival and neurological recovery with mild induced
hypothermia, also called therapeutic hypothermia (TH),
after cardiac arrest [6, 7]. In 2002, two randomised clin-
ical studies demonstrated that TH, with cooling of the
patient to 32–34 °C, decreased mortality and improved
neurological function in unconscious OHCA survivors [8,
9] This led to a progressive and widespread implementa-
tion of TH as a standard treatment in comatose OHCA
patients, and its use was recommended by international
resuscitation guidelines for all comatose post-anoxic sur-
vivors, regardless of the location of arrest and the initial
rhythm [10]. The exact neuroprotective mechanisms of
TH on the ischaemia-reperfusion injury have not been
fully elucidated, but they involve, among other processes,
a reduction of brain metabolism, the attenuation of glu-
tamate and dopamine release and the inhibition of apop-
tosis [11–14].
Based on international consensus, the term therapeutic
hypothermia has now been replaced with the term targeted
temperature management (TTM) [15]. One unresolved
issue concerning the use of TTM after cardiac arrest is the
optimal duration of cooling. In the large randomised con-
trolled trials (RCTs) [6, 7, 16], cardiac arrest (CA) survivors
were cooled for between 12 and 24 hours. However, experi-
mental data suggest an additional cerebral benefit from
prolonged cooling (for 48 hours or longer). In a CA swine
model, Suh et al. showed that the application of TTM for
48 hours resulted in a higher attenuation of neuronal
apoptosis when compared to 24-hour treatment [17]. In
a rat CA model, histological assessment of neuronal
survival revealed a greater neuroprotection with pro-
longed (48 hours) TTM compared to 24-hour interven-
tion [18]. In adult patients, there are no randomised
trials investigating the effect of prolonged TTM. A
small number of observational studies showed no dif-
ference in mortality or poor neurological outcome [19,
20], but prolonged TTM of up to 72 hours was feasible
and safe and associated with a less pronounced burden
of inflammatory response during rewarming in patients
suffering from post-anoxic brain injury [21]. Consider-
ing the scientific equipoise between 24-hour and a lon-
ger duration of cooling in the CA setting, we designed
a trial aiming to test whether 48 hours of TTM at 33 ±
1 °C is superior to 24-hour therapy in unconscious
OHCA survivors. In addition, we aimed to assess the
safety of prolonged cooling, in particular in regard to
the occurrence of adverse reactions and prolongation of
ICU care. This manuscript is prepared according to the
SPIRIT guidelines [22].
Objective
The aim of this study is to investigate the effects of a pro-
longed duration (48 hours) of TTM at 33 ± 1 °C (TTM33)
in unconscious OHCA patients compared to standard ther-
apy (24 hours).
Hypothesis
We hypothesise that cooling for 48 hours results in a higher
proportion of CA patients with good neurological recovery
(assessed by the Cerebral Performance Category score
(CPC) [23, 24], Table 1.) at 6 months compared to 24 hours
therapy. CPC 1–2 is defined as a good neurological out-
come and CPC 3–5 as a poor neurological outcome.
Trial design
The TTH48 study is a pragmatic, randomised, prospective,
assessor-blinded, multicentre trial with two arms: a control
arm (24 hours’ TTM33) and an intervention arm (48 hours’
TTM33).
Methods: participants, intervention and outcomes
Study setting
The TTH48 study is currently ongoing in eight ICUs at
seven hospitals in six European countries. The partici-
pating institutions are listed at the homepage of the trial
(www.tth48.com), and the trial has been registered at
www.clinicaltrials.gov NCT01689077).
Eligibility criteria
All unconscious OHCA patients entering the ICUs are
screened for inclusion criteria. Informed consent and ran-
domisation to one of the two interventional arms should
occur within the first 23 hours after a body temperature of
34 °C or colder is reached. Informed consent will be ob-
tained from all participants.
Patients must meet all the following inclusion criteria:
1. Age over 17 years and below 80 years
2. OHCA with a presumed cardiac origin
3. Sustained spontaneous circulation after resuscitation
(no need for cardiac compressions during 20 min and
clinical signs of circulation)
4. Glasgow Coma Score (GCS) [25] <8 on admission
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The inclusion criteria include, as opposed to those in
previous RCTs [8, 9], both patients with shockable and
non-shockable rhythms.
Patients fulfilling one of the following criteria are
excluded:
1. Estimated time interval from collapse to return of
spontaneous circulation over 60 min
2. CA with presumed non-cardiac cause (e.g. trauma,
aorta dissection, intracerebral disease, massive bleeding,
hanging or hypoxemia)
3. In-hospital cardiac arrest
4. Terminal disease or ‘not-to-be reanimated’ orders
5. Severe coagulopathy (anticoagulant therapy,
including thrombolysis, is not an exclusion criteria)
6. Unwitnessed OHCA with asystole as first rhythm
7. Time from cardiac arrest to initiation of cooling
longer than 240 min
8. Pregnancy
9. Previous neurological disease with cognitive
impairment
10. Persistent cardiogenic shock, systolic blood pressure
<80 mmHg despite vasoactive treatment and/or
aortic balloon pump intervention
11. Suspected or confirmed acute intracerebral bleeding
12. Suspected or confirmed acute stroke
13. Acute coronary artery bypass surgery
14. Lack of consent from next of kin or general
practitioner/medical officer of health or from the
patient if they wake up and is capable. This criterion
should be used in accordance with local ethical
requirements
Interventions
The use of TTM should be initiated as quickly as pos-
sible, if possible within 60 min after the return of spon-
taneous circulation (ROSC). There are no restrictions on
the methods to be used to induce TTM. The maximal
amount of cold fluids (4 °C) to be given in these patients
is 30 ml/kg, particularly for TTM induction. The target
temperature is set at 33 ± 1 °C and measured in the blad-
der, rectum, nasopharynx or blood, according to local
practices. The achievement of the target temperature is
considered at a body temperature of 34 °C or colder. At
the end of the cooling period, rewarming is progressively
achieved at 0.5 °C/h until a body temperature of 37 °C is
reached. At that moment, sedative/analgesic agents are
stopped and neurological assessment (including clinical
examination and additional prognostic tools) of the pa-
tient is conducted daily. Patients who eventually wake
up and are extubated are observed for at least 24 hours
before ICU discharge.
Withdrawal of active treatment
All active treatment is continued until 72 hours after
normothermia has been reached. Exceptions to this may
include patients who develop clinical signs of brain death
or refractory shock with multiple organ dysfunctions. In
addition, patients with previously unrecognised terminal
cancer at the initiation of treatment may undergo a limita-
tions on life-sustaining therapies procedure (LLSTP) in the
event that further medical treatment is considered
unethical. These decisions are made by the attending
physician in a multidisciplinary fashion (e.g. including
neurologists and neurophysiologists whenever possible),
independently from the research team. Patients who remain
comatose 72 hours after normothermia are assessed with a
combination of daily neurological examination (including
at least the evaluation of motor response to noxious
stimuli and pupillary/corneal reflexes), continuous or
repeated intermittent electroencephalogram (EEG) and
somatosensory evoked potentials (SSEPs). The decision
to initiate LLSTP is based on agreement among the
participating centres [26].
Table 1 Cerebral Performance Categories Score
CPC1. Good cerebral performance
Conscious. Alert, able to work and lead a normal life. May have minor psychological or neurological deficits (mild dysphasia, non-incapacitating
hemiparesis, or minor cranial nerve abnormalities)
CPC 2. Moderate cerebral disability
Conscious. Sufficient cerebral function for part-time work in a sheltered environment or independent activities of daily life (dressing, traveling by
public transportation, and preparing food). May have hemiplegia, seizures, ataxia, dysarthria, dysphasia, or permanent memory or mental changes
CPC 3. Severe cerebral disability
Conscious. Dependent on others for daily support because of impaired brain function (in an institution or at home with exceptional family effort). At
least limited cognition. Includes a wide range of cerebral abnormalities from ambulatory with severe memory disturbance or dementia precluding
independent existence to paralytic and able to communicate only with eyes, as in the locked-in syndrome
CPC 4. Coma, Vegetative state
Not conscious. Unaware of surroundings, no cognition. No verbal or psychological interactions with environment
CPC 5. Death
Certified brain dead or dead by traditional criteria
Kirkegaard et al. Trials  (2016) 17:228 Page 3 of 9
Interruption of hypothermic procedures
There is a possibility that the cooling treatment may be
associated with uncontrolled bleeding, life-threatening
arrhythmias or refractory low cardiac output (e.g. despite
maximal inotropic/vasopressor therapy). If one of these
complications should occur, the cooling treatment can
be stopped according to the decision of the attending
physicians and medical team, independently from the
research team. The excluded patient will then be kept at
36 °C throughout the intervention period and considered
in the treatment arm of randomisation for final outcome
according to the intention-to-treat analysis.
Concomitant therapies
Concomitant medication will follow local guidelines and
may vary between study sites. Sedation is managed with
propofol or midazolam and analgesia with remifentanyl
or fentanyl. The use of neuromuscular blocking agents
(cisatracurium or rocuronium) is recommended until
the target temperature is achieved, and it should only be
continued thereafter if needed (e.g. if shivering occurs).
Convulsions should be aggressively treated with sedative
agents and anti-epileptic drugs according to standard
operating procedures. Mean arterial pressure (MAP)
should be targeted above 60–65 mmHg. If circulatory
support is needed, the choice of the inotropic/vasopres-
sor agent is dependent on the attending physician. Blood
glucose should be maintained between 6 and 10 mmol/l
using glucose or insulin infusion administered intraven-
ously, if required.
Outcome
The primary outcome of the study is the proportion of
patients with good neurological outcome (CPC 1–2) at
6 months after CA (Table 1). The CPC assessment will
be scored during a semi-structured telephone interview
or person-to-person interview performed by an assessor
blinded to the treatment allocation.
Secondary outcomes: (Fig. 1)
1. CPC at hospital discharge and at 30 and 90 days
2. GCS on day 4 and at hospital discharge
3. Mortality (CPC 5 at 6 months)
4. Adverse reactions (Table 2)
5. Progression of GCS from days 1 to 7 in the ICU and
at ICU discharge
Sample size
Assuming a proportion of patients with good cerebral
outcome (CPC 1–2) following a 24-hour TTM treatment
of 50 % [8, 9] and an expected absolute 15 % difference
in the good outcome rate between the groups (two-
sided), 169 patients in each group (n = 338) would be
required to have a study power of 80 % and a 5 % signifi-
cance. However, this power calculation does not take
into consideration possible missing outcome data, and
thus the total number of patients in the study is in-
creased to 350.
Recruitment
Patient screening and inclusion started on 1 February 2013.
Recruitment is ongoing and, as of 1 February 2016, 304
patients have been included and randomised into one of
two groups. Allocation of the last of the 350 patients is
anticipated to be late May 2016 (Fig. 2).
Methods: assignment of intervention
Allocation
The centres will have access to a web-based randomisation
procedure (Trial Partner, Institute for Clinical Medicine,
Aarhus University, Denmark). Each patient will receive his
or her own randomisation number. Randomisation is bal-
anced at a 1:1 ratio and will take place in blocks of random
size, stratified according to the study site, age (above and
below 60 years) and initial rhythm (shockable versus non-
shockable rhythm).
Sequence generation
The randomisation process was created by a data
manager not involved in patient recruitment. The
screening and randomisation procedure was built in a
web-based chart record form, sampling data from the
study (e-CRF).
Fig. 1 Outcome. Outcome assessment over the study period
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Blinding
The registration and measurement of 6-month CPC are
done by research staff members who are blinded to the
study treatment arm. Registration of adverse events and
GCS scores, while the patient is in the ICU, is performed
by the treating physician team and research staff, who
are not blinded to the treatment group since the attend-
ing staff cannot be blinded to the intervention.
Table 2 Adverse events. Adverse events and definitions, reported from day 1 to discharge from the primary hospital
Adverse events Definitions
Cerebral Pupils Reacting to light, dilated (size), dilation difference between eyes
Seizure Involuntary contractions or series of contractions of the voluntary muscles
Myoclonus Short lasting involuntary contractions of one or several muscles
Myoclonus state Continuous myoclonus
Convulsive state Continuous seizures or continuous seizure pattern on EEG
Circulation Hypotension Mild: MAP >60 mmHg with one inotropic agent and volume infusion
Moderate: MAP >60 mmHg with full treatment
Severe: MAP 50–60 mmHg despite full treatment
Circulatory failure: MAP <50 mmHg for more than 10 min despite full
treatment
Need for pacing
Resuscitation
Arrhythmias Mild Arrhythmias that do not demand treatment
Moderate Stable haemodynamics (MAP >60 mmHg) with treatment
Severe Pulseless VT/VF or unstable haemodynamics despite treatment
Gastrointestinal Mild Aspiration, can partly take enteral nutrition
Moderate Aspiration more than 400 ml, cannot take any enteral nutrition
Severe Ileus, bleeding gastric ulcer, need for explorative laparotomy or others
Urological Continuous or
intermittent
replacement
therapy
Infectious/inflammatory Pneumonia New or progressing infiltrations on thoracic X-ray
Fever (not during hypothermia treatment)
Leucocytosis
Purulent tracheobronchial secretion
SIRSa At least 2 of 4 SIRS criteria present
Sepsis Sepsis, SIRS caused by an infection
Severe sepsis Sepsis associated with organ dysfunction
Septic shock Sepsis with hypotensionb
Bleeding and transfusion Bleeding Mild: no transfusion needed
Moderate: up to two RBC units/24 hours.
Severe: more than two RBC units/24 hours
Critical bleeding in organs: intracranial, intrathecal, intraocular or
pericardial
Other bleeding: retroperitoneal, thorax or solid organs
Transfusion Number of transfusions
EEG electroencephalogram, MAP mean arterial pressure, VF ventricular fibrillation, VT ventricular tachycardia
aSIRS: temperature >38 °C or <36 °C, pulse rate >90 beats/min, respiratory rate >20 breath/min or PaCO2 < 4.3 kPa or need for mechanical ventilation, leucocytes >12,000
cells/mm3, or <4000 cells/mm3, or >10 % immature cells
RBC: red blood cell
bsystolic blood pressure <90 mmHg or a reduction >40 mmHg from baseline and perfusions abnormalities or need for vasoactive drugs despite adequate volume
treatment in the absence of other reasons for hypotension
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Information about the intervention group is limited to
those treating the patients. Relatives and patients are not
blinded to the intervention.
Methods: data collection, management and
analyses
Data collection and management (Fig. 3)
Data collection follows the Utstein style [27]. The study
data are entered online in an Internet-based database and
collected from hospital records, ambulance records and
national databases. It is, therefore, assumed that the re-
search staff have access to these data sources, including
the electronic medical records (EMR). Each centre is
responsible for: (1) screening and registration of all coma-
tose OHCA patients admitted to the ICU, (2) randomisa-
tion, (3) treatment, (4) collection and entry of data
according to the study protocol and the e-CRF, and (5)
obtaining informed consent. Any violation/deviation of
the protocol must be recorded in the e-CRF. The trial data
comprise e-CRF data extracted by the data manager in co-
operation with the principal investigator of the study. The
data are made accessible on an international open data-
base (ClinicalTrials.gov) and kept for 15 years after com-
pletion of data collection for the basic study and then
destroyed.
Statistical methods
The primary outcome measure CPC will be divided into
two groups: group 1 = patients with a good neurological
outcome (CPC 1–2); group 2 = patients with a poor neuro-
logical outcome (CPC 3–5). Categorical data (group 1 and
group 2 outcomes) will be compared using a chi-square
test. Continuous parameters/data will be assessed for nor-
mality and compared using the Student’s t test or Mann-
Whitney U test, accordingly. A p value <0.05 is considered
statistically significant. Secondary outcome measures will
be compared between groups using non-parametric or
parametric tests. Descriptive statistics will be calculated for
the two groups. A predefined plan for further data analyses
will be prepared in collaboration with a biostatistician. Data
will be analysed according to the ‘intention-to-treat’
principle. The report will encompass the data recom-
mended by the Consolidated Standards of Reporting Trials
(CONSORT) Statement for non-pharmacological treatment
interventions.
Methods: monitoring
Data monitoring
The trial is followed by a Data and Safety Monitoring
Committee (DSMC). When 175 of the 350 patients have
been allocated, a safety interim analysis will be performed
comparing serious adverse reactions (SAR), including
death, between the two arms of the trial. Blinded data will
be analysed by an independent statistician and provided to
the DSMC. Based on the analyses of SAR, the DMSC will
use the Haybittle-Peto statistical approach to guide its
Fig. 2 Inclusion rate. Inclusion rate up to the first 304 patients
(1 February 2016). Allocation of the last of the 350 patients is
anticipated to be late May 2016. The solid line represents included
patients; the broken line represents the expected inclusion rate
Fig. 3 Trial overview. Trial overview according to the two interventional arms
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recommendations regarding early termination or continu-
ation of the trial. If appropriate, the DSMC may receive
un-blinded data. The Trial Steering Committee, compris-
ing up to two members from each centre and the principal
investigator as the chairman of the committee, will make
the final decision regarding the continuation or discon-
tinuation of the trial. Further interim analyses will be
based on the recommendations of the DSMC.
The safety analyses have been performed and the DSMC
had no comments, but recommended a safety interim
analysis comparing the main outcome parameter CPC at
6 months for the first 175 patients.
Harm
Each year throughout the trial, the principal investiga-
tor must submit a list to the ethical committee in the
Central Denmark Region of all serious expected/unex-
pected adverse events that have occurred during the
period. This information must be accompanied by an
assessment of the subjects’ safety.
Ethics and dissemination
Ethical approval
The protocol was approved by:
The Ethics Committee of Central Denmark Region on
2 January 2011 (journal number 20110022).
The Regional Ethics Committee of Western Norway
on 9 October 2013 (ref 2013/1486).
The Ethical Committee of Helsinki and Uusimaa Hospital
District on 21 October 2014 (§157).
The Tallinn Ethical Committee, Estonia on 10 March
2015 (approval number. 943).
The Ethics Committee of the Hôpital Erasme, Brussels,
Belgium on 9 March 2015 (021/406).
The Ethics Committee of the Charité-Universitätsmedizin,
Berlin on 2 August 2015 (EA2/080/15).
The trial is performed according to the current version
of the Helsinki Declaration (2013). The study is conducted
in accordance with the present protocol, the ICH-GCP
guidelines and the regulatory requirements that apply to
the study.
Withdrawal of consent
Patients who wake up will be informed verbally and in
writing about the study they are participating in and
asked to continue in the study. If a patient refuses, he or
she will be asked for permission to use the data collected
before the withdrawal of his or her consent and for per-
mission to collect primary data, i.e. CPC after 6 months.
Confidentiality
The trial protocol is approved by The Danish Data Protec-
tion Agency.
Dissemination policy
The results of the study will be published in a peer-
reviewed international medical journal.
Discussion
Current resuscitation guidelines recommend TTM treat-
ment aiming at a target temperature of between 32 and
36 °C for at least 24 hours in patients after OHCA [28, 29].
The guidelines also emphasise the need for more data on
the optimal depth and length of cooling procedures after
CA [27, 28]. The present study compares 48-hour therapy
to 24-hour TTM therapy at 33 ± 1 °C. The standard length
of TTM in Europe is 24 hours, and this duration was,
therefore, selected as the standard care in the control
group [30]. The reason that 48-hour duration was chosen
for the intervention arm is based on various consider-
ations. Prolonged cooling has been shown to be beneficial
in neonates and newborns, where treatment duration
is around 72 hours. A meta-analysis including 11 ran-
domised trials showed a statistically significant reduction
in the combined outcome of mortality or major neuro-
developmental disability in patients until 18 months of
age [31] compared to those maintained at normothermia.
In most studies, cooling duration was 72 hours, and in
two studies it was 48 hours. Thus, we considered it to be
reasonable to prolong therapy for 48 hours, where a
longer duration of cooling may be more effective but may
have a higher likelihood of developing complications, such
as infection. Recently, Kagawa and colleagues published a
retrospective study on the duration of TTM, targeting a
temperature of 33 °C. They compared patients who had
been treated for shorter or longer than 28 hours and
found no benefit but an increased risk of pneumonia and
arrhythmia with longer treatment. However, this was a
retrospective study, which makes it prone to bias since it
is possible that patients with prolonged resuscitations
were treated for longer periods of time [32].
Regarding inclusion and exclusion criteria, we decided to
exclude patients for whom treatment could not be initiated
within 240 min following arrest. The evidence regarding
whether prompt or delayed TTM benefits patients is incon-
clusive, and it is impossible to evaluate in an observational
trial since patients suffering more severe injuries may more
easily show a decrease in temperature. As we did not know
the optimal time window for beginning TTM in OHCA
patients, we therefore set the relatively restrictive time limit
of 240 min.
In addition, in the present trial we decided to exclude
patients with a delay in the ROSC exceeding 60 min. The
Hypothermia After Cardiac Arrest (HACA) trial focused
on patients with a delay in the ROSC of less than 35 min,
whereas the recent TTM trial by Nielsen and colleagues
included patients with up to 170 min of cardiopulmonary
resuscitation (CPR) [16, 33]. Some previous studies have
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indicated that TTM is more effective with shorter delays
in the ROSC [34]. Thus, in the present study we decided
to limit inclusion to patients with delays in the ROSC
shorter than 60 min.
The cooling methods
Similar to previous TTM trials [16], the TTH48 is planned
as a pragmatic RCT. The participating centres can use
either intravenous or superficial cooling methods according
to local practices. It has been demonstrated that the use of
invasive cooling devices results in a tighter temperature
control compared to other tools [35], but neither of the two
observational or the one randomised study comparing
superficial versus intravenous cooling methods showed any
effect on neurological outcome between the two techniques
[36, 37]. Concerning the rewarming rate, various papers
recommend a controlled increase in body temperature not
exceeding 0.25 to 0.50 °C/h. Thus, we selected 0.5 °C/h,
considering the lack of evidence on the optimal therapeutic
approach for this issue. Importantly, a recent experimental
study concluded that a rapid rewarming rate of 2.0 °C/h
abolished all the beneficial effects of TTM, but this did not
occur when the rewarming rate was set at 0.5–1.0 °C/h
[38].
In conclusion, this is the first randomised clinical study
conducted in adult OHCA patients comparing two differ-
ent durations (24 and 48 hours) of TTM at 33 ± 1 °C. This
study will provide information regarding whether this is
associated with clinical benefit as well as relevant adverse
events.
Trial status
Three hundred and four patients have been randomised
by 1 February 2016 (Fig. 2). Allocation of the last of the
350 patients is anticipated to be late May 2016. Collec-
tion of outcome data will end late November 2016.
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